[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Ethics::
Contact us::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Index






     
 
..
:: Volume 21, Issue 1 (Spring 2019) ::
EBNESINA 2019, 21(1): 44-50 Back to browse issues page
Validation of the Addenbrooke’s Cognitive Examination III (ACE-III) in Alzheimer’s disease and Mild Cognitive Impairment
Majid Mahmoud alilou , Soheila Parvaz , Zeinab Khanjani , Touraj Hashemi
Department of educational science and psychology University of Tabriz, Tabriz, Iran , parvazsoheyla@yahoo.com
Abstract:   (2694 Views)
 Background: A clinical tool for detecting early signs of cognitive degeneracy in the elderly population can help clinicians to identify dementia in the early stages. This research was aimed to validate the Persian version of Addenbrooke’s Cognitive Examination-III (ACE-III) in patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in a group of Iranian population.
Materials and methods: A total of 135 subjects (AD= 30, MCI=30 and 75 normal control) that met inclusion criteria participated in the study. All patients were diagnosed by neurologist using neuroimaging tools and routine clinical examination. Data were analyzed using receiver operating characteristic (ROC) curves, Pearson’s correlation analysis and multivariate analysis of variance (MANOVA).
Results: ACE-III at cut-off point of 75 showed 99% sensitivity and 95% specificity in discriminating AD from the normal group and at cut-off point of 82 showed 92% sensitivity and 90% specificity in discriminating MCI from normal controls. Test-retest reliability showed a correlation of 0.94 for both AD and MCI. Internal consistency using Cronbach’s alpha was 0.97. A significant difference was seen between AD and control group on total score and all ACE-III components (attention, memory, language, verbal fluency and visuospatial function). MCI group was differed from control group on memory and visiouspatial components.
Conclusion: The Persian version of ACE-III is a reliable and useful cognitive screening tool for diagnosis of dementia and has a high specificity.
Keywords: Mental Status and Dementia Tests, Alzheimer Disease, Cognitive Dysfunction
Full-Text [PDF 695 kb]   (841 Downloads)    
Type of Study: Original |
Received: 2018/01/10 | Accepted: 2019/04/15 | Published: 2019/04/15
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mahmoud alilou M, Parvaz S, Khanjani Z, Hashemi T. Validation of the Addenbrooke’s Cognitive Examination III (ACE-III) in Alzheimer’s disease and Mild Cognitive Impairment. EBNESINA 2019; 21 (1) :44-50
URL: http://ebnesina.ajaums.ac.ir/article-1-615-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 1 (Spring 2019) Back to browse issues page
ابن سینا EBNESINA
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4645